期刊文献+

RUNX3与Survivin在子宫内膜癌中的表达 被引量:1

Expression of RUNX3 and Survivin in Endometrial Carcinoma
下载PDF
导出
摘要 目的探讨RUNX3和Survivin在子宫内膜癌(endometrial carcinoma,EC)组织中的表达。方法采用免疫组化链霉菌抗生物素蛋白-过氧化物酶连结法(streptavidin-peroxidase,SP)检测20例正常增生期子宫内膜、20例非典型增生子宫内膜、60例EC组织中RUNX3和Survivin蛋白的表达,比较其差异。结果在EC中,RUNX3和Survivin蛋白的阳性表达率分别是25.0%(15/60)和91.7%(55/60),随着组织学分级升高及分期进展,RUNX3阳性表达率逐渐降低(χ2=16.275,P=0.000),而Survivin蛋白表达逐渐升高(χ2=6.251,P=0.044),两者阳性表达率均与肌层浸润深度、淋巴结转移及有无脉管浸润无关(P均>0.05)。Survivin蛋白在EC中的阳性表达率91.7%(55/60)明显高于正常增生期15.0%(3/20)和非典型增生子宫内膜65.0%(13/20)(χ2=44.221,P=0.000;χ2=8.848,P=0.000),其中正常增生期与非典型增生子宫内膜Survivin蛋白表达阳性率有统计学差异(χ2=8.640,P=0.003)。RUNX3蛋白在EC中的阳性表达率25.0%(15/60)明显低于正常增生期90.0%(18/20)和非典型增生子宫内膜60.0%(12/20)(χ2=26.151,P=0.000;χ2=8.218,P=0.004),正常增生期与非典型增生子宫内膜RUNX3蛋白阳性表达率无统计学差异(χ2=3.333,P=0.068)。结论 EC中RUNX3蛋白表达较低或缺失,Survivin蛋白表达较高。 Objective To investigate the expression of RUNX3 and Survivin protein in endomctrial carcinoma (EC). Methods The expression of RUNX3 and Survivin protein in endometrial carcinoma( EC, n = 60) , atypical endometrial hyperplasia (n = 20) and normal endometrial tissues (n = 20) were examined by immunohistochemistry (SP method). Results In EC, the positive expression rates of RUNX3 and Survivin were 25.0% (15/60) and 91.7% (55/60) , respectively. With the histological grade increasing and FIGO stage progressing, the positive expression rate of RUNX3 decreased (χ^2=16. 275, P = 0. 000) , and that of Survivin increased (χ^2= 6. 251, P = 0. 044). The expression of RUNX3 and survivin were not related to the depth of muscular invasion, lymph node metastasis and lymphatic vessel invasion( all P 〉 0.05). The positive expression rate of Survivin protein in EC (91.7% ,55/60) was significantly higher than that in normal proliferative endometrium( 15.0%, 3/20) and atypical endometrial hyperplasia(65.0% ,13/20)(χ^2= 44. 221, P = 0. 000; χ^2= 8. 848, P = 0. 000), and between normal endometrium and atypical endometrial hyperplasia, the positive expression rate of Survivin protein was also significant different (χ^2= 8. 640, P = 0. 003 ). Whereas, the positive rate of RUNX3 in EC (25.0% , 15/60) was significantly lower than that in normal proliferative endometrium (90.0% , 18/20) and atypical endometrial hyperplasia (60.0% , 12/20) (χ^2= 26. 151, P = 0. 000; χ^2= 8. 218, P = 0. 004 ), and between normal proliferative endometrium and atypical endometrial hyperplasia, the positive expression rate of RUNX3 protein was not significantly different(χ^2= 3. 333, P = 0. 068 ). Conclusion The expression of RUNX3 protein is lower or absent in EC, but the expression of Survivin protein is higher.
出处 《中国微创外科杂志》 CSCD 2012年第5期450-453,共4页 Chinese Journal of Minimally Invasive Surgery
关键词 子宫内膜癌 RUNX3 SURVIVIN 免疫组织化学 Endometrial carcinoma RUNX3 Survivin Immunohistochemistry
  • 相关文献

参考文献13

  • 1Kellert IM, Botterweck AA, Huveneers JA,et al. Trends in incidence of and mortality from uterine and ovarian cancer in Mid and South Limburg,The Netherlands, 1986 -2003. Eur J Cancer Prey,2009, 18(1) :85-89.
  • 2Levanon D, Negreanu V, Bernstein Y, et al. AML1, AML2 and AML3,the Human Member of the Runt Domain gene family:cDNA structur, expression and chromosomal localization. Genomic, 1994,23 (2) :425 -432.
  • 3Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene Survivin expressed in cancer and lymphoma. Nat Med, 1997,3 ( 8 ) : 917 -921.
  • 4杨琼娇,许淑媛,黄晓明,邓瑰.RUNX3和Survivin在卵巢上皮性癌中的表达及其临床意义[J].临床和实验医学杂志,2011,10(2):87-89. 被引量:4
  • 5Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol, 1983,15 : 10 - 17.
  • 6Fukamachi H. Runx3 controls growth and differentiation of gastric epithelial cells in mammals. Dev Growth Differ,2006,48( 1 ):1 -13.
  • 7Li J, Kleeff J, Guweidhi A. RUNX3 expression in primary and metastatic pancreatic cancer. J Clin Patho1,2004,57 (3) :294 - 299.
  • 8郭真理,陈柯,王晓秋,胡闻.子宫内膜样腺癌中MDM2、EZH2和RUNX3的表达及其相关性[J].临床与实验病理学杂志,2010,26(6):688-692. 被引量:7
  • 9乔玉环 冯秀丽.RUNX3和EZH2蛋白在子宫内膜腺癌组织中的表达[J].郑州大学学报,2010,30(5):90-93.
  • 10Yoshizaki T, Enomoto T, Fujita M, et al. Frequent inactivation of RUNX3 in endometrial carcinoma. Gynecol Oncol,2008,110 (3) : 439 - 444.

二级参考文献24

  • 1Kuzmichev A,Jenuwein T,Tempst P,et al.Different EZH2-containing complexes target methylation of histone H1 or nucleosomal histone H3[J].Mol Cell,2004,14(2):183-93.
  • 2Tang X,Milyavsky M,Shats I,et al.Activated p53 suppresses the histone methyltransferase EZH2 gene[J].Oncogene,2004,23(34):5759-69.
  • 3Fukamachi H.Runx3 controls growth and differentiation of gastric epithelial cells in mammals[J].Dev Growth Differ,2006,48(1):1-l3.
  • 4Zaidi S K,Sullivan A J,van Wijnen A J,et al.Integration of Runx and Smad regulatory signals at transcriptionally active subnuclear sites[J].Proc Natl Acad Sei USA,2002,99(12):8048-53.
  • 5Yoshizaki T,Enomoto T,Fujita M,et al.Frequent inactivation of RUNX3 in endometrial carcinoma[J].Gynecologic Oncology,2008,(110):439-44.
  • 6Fujii S,Ito K,Ito Y,et al.Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation[J].J Biol Chem,2008,283(25):17324-32.
  • 7Chi X Z,Kim J,Lee Y H,et al.Runt-related transcription factor RUNX3 is a target of MDM2-mediated ubiquitination[J].Cancer Res,2009,69(20):8111-9.
  • 8Lahav G,Rosenfeld N,Sigal A,et al.Dynamics of the p53-Mdm2 feedback loop in individual cells[J].Nat Genet,2004,36(2):147-50.
  • 9Morgan R J,Newcomb P V,Hardwick R H,et al.Amplification of cyclin D1 and MDM-2 in oesophageal carcinoma[J].Eur J Surg Oncol,1999,25(4):364-7.
  • 10Bangson C, Rubins N, Glusman G, et al. The RUNX3 genesequence structure and regHlated expression [ J ]. Gene, 2001, 279 ( 2 ) : 221 - 232.

共引文献9

同被引文献8

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部